Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $8.00 Average PT from Brokerages

Sana Biotechnology, Inc. (NASDAQ:SANA) has been given a consensus rating of “Buy” by the six ratings firms that are covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have covered the stock in the last year is $8.00.

SANA has been the subject of several research reports. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 target price on shares of Sana Biotechnology in a research report on Tuesday, June 24th. Morgan Stanley initiated coverage on Sana Biotechnology in a research report on Thursday, July 3rd. They issued an “overweight” rating and a $12.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Sana Biotechnology in a research report on Thursday, April 24th.

Sana Biotechnology Trading Down 2.9%

Shares of NASDAQ:SANA opened at $3.33 on Monday. The business has a 50-day moving average price of $3.56 and a 200 day moving average price of $2.69. The company has a market capitalization of $791.91 million, a price-to-earnings ratio of -3.14 and a beta of 1.90. Sana Biotechnology has a 12-month low of $1.26 and a 12-month high of $7.30.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. As a group, equities research analysts predict that Sana Biotechnology will post -1.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sana Biotechnology

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Corient Private Wealth LLC boosted its stake in shares of Sana Biotechnology by 264.7% in the 2nd quarter. Corient Private Wealth LLC now owns 1,136,000 shares of the company’s stock valued at $3,101,000 after buying an additional 824,505 shares during the period. Captrust Financial Advisors boosted its stake in shares of Sana Biotechnology by 43.8% in the 2nd quarter. Captrust Financial Advisors now owns 15,793 shares of the company’s stock valued at $43,000 after buying an additional 4,807 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Sana Biotechnology by 46.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 15,444 shares of the company’s stock valued at $42,000 after buying an additional 4,931 shares during the period. Brevan Howard Capital Management LP boosted its stake in shares of Sana Biotechnology by 85.3% in the 2nd quarter. Brevan Howard Capital Management LP now owns 260,723 shares of the company’s stock valued at $712,000 after buying an additional 120,016 shares during the period. Finally, Adage Capital Partners GP L.L.C. purchased a new position in shares of Sana Biotechnology in the 2nd quarter valued at about $1,916,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.